According to a study issued in 'Immunopharmacology and Immunotoxicology', the effectiveness of guluronic acid in combination with conventional therapy has been highlighted with more desirable safety profile as compared to conventional-treated patients as explained from routine rheumatology clinical practice data. Shahin Khadem Azarian and researchers assessed the safety, efficacy and tolerability of guluronic acid (G2013) for the treatment of rheumatoid arthritis patients who had an inappropriate response to conventional drugs.

This randomized, 12-week clinical trial comprised of two treatment arms: guluronic acid (G2013) and conventional treatment. The diagnosed RA patients as per the ACR/European League against Rheumatism 2010 classification criteria with active disease at baseline who had an inadequate response to conventional therapy were included in this study. Guluronic acid, 500 mg, was administered twice daily for 12 weeks. Then, the patients were followed up for safety and efficacy.
The mean changes in guluronic acid and control groups were −7.54 and −2.5 for the tender joint count; −23.18 and −1.81 for patient global assessment; −7.59 and −3.59 for the swollen joint count; −30 and −0.9 for physician global assessment; −14.45 and −1.45 for erythrocyte sedimentation rate.  Guluronic acid depicted more significant improvements than those with conventional drugs. All in all, around15.3% of guluronic acid-treated patients and 69.2% of conventional-treated patients experienced adverse events (AEs).

"Guluronic acid therapy could be a suitable choice for RA disease management", noted the study researchers.